Skip to content

Non-Hodgkin's Lymphoma

Font Size

Treatment for Indolent, Noncontiguous Stage II / III / IV Adult NHL

    Optimal treatment of advanced stages of low-grade non-Hodgkin lymphoma is controversial because of low cure rates with the current therapeutic options. Numerous clinical trials are in progress to settle treatment issues, and patients should be urged to participate. The rate of relapse is fairly constant over time, even in patients who have achieved complete response to treatment. Indeed, relapse may occur many years after treatment. Currently, no randomized trials guide clinicians about the initial choice of watchful waiting, rituximab, nucleoside analogs, alkylating agents, combination chemotherapy, radiolabeled monoclonal antibodies, or combinations of these options.[1]; [2][Level of evidence: 1iiDiii]

    For patients with indolent, noncontiguous stage II and stage III non-Hodgkin lymphoma, central lymphatic radiation therapy has been proposed but is not usually recommended as a form of treatment.[3,4]

    Recommended Related to Non-Hodgkin's Lymphoma

    Diffuse Large B-Cell Lymphoma

    Diffuse large B-cell lymphoma is a cancer that starts in white blood cells called lymphocytes. It is also called DLBCL. It usually grows in lymph nodes -- the pea-sized glands in your neck, groin, armpits, and elsewhere that are part of your immune system. It can also show up in other areas of your body. DLBCL grows fast, but 3 out of 4 people are disease-free after treatment, and about half are cured. And researchers are working to make treatments even better.  There are two types of lymphoma:...

    Read the Diffuse Large B-Cell Lymphoma article > >

    Numerous prospective clinical trials of interferon-alpha, including SWOG-8809, have shown no consistent benefit; the role of interferon in patients with indolent lymphoma remains controversial.[5,6,7,8,9,10,11,12,13,14,15,16]

    Standard Treatment Options for Indolent, Noncontiguous Stage II/III/IV Adult NHL

    Standard treatment options for indolent, noncontiguous stage II/III/IV adult NHL include the following:

    1. Watchful waiting for asymptomatic patients.
    2. Rituximab.
    3. Purine nucleoside analogs.
    4. Alkylating agents (with or without steroids).
    5. Combination chemotherapy.
    6. Yttrium-90-labeled ibritumomab tiuxetan and iodine-131-labeled tositumomab.
    7. Maintenance rituximab.

    Watchful waiting for asymptomatic patients

    The rate of relapse is fairly constant over time, even in patients who have achieved complete responses to treatment. Indeed, relapse may occur many years after treatment. In this category, deferred treatment (i.e., watchful waiting until the patient becomes symptomatic before initiating treatment) should be considered.[2,17,18,19]

    Evidence (watchful waiting):

    1. Three randomized trials compared watchful waiting to immediate chemotherapy.[18,20]; [21][Level of evidence: 1iiA]
      • All three trials showed no difference in cause-specific or overall survival (OS).
      • For patients randomly assigned to watchful waiting, the median time to require therapy was 2 to 3 years and one-third of patients never required treatment with watchful waiting (half died of other causes and half remained progression-free after 10 years).
    2. The PRIMA trial compared watchful waiting to immediate rituximab, the anti-CD20 monoclonal antibody, with or without maintenance doses.
      1|2|3|4

      Today on WebMD

      stem cells
      What are they and why do we need them?
      Lung cancer xray
      See it in pictures, plus read the facts.
       
      sauteed cherry tomatoes
      Fight cancer one plate at a time.
      Ovarian cancer illustration
      Do you know the symptoms?
       
      Vitamin D
      SLIDESHOW
      New Treatments For Non-Hodgkins Lymphoma
      FEATURE
       
      Lifestyle Tips for Depression Slideshow
      SLIDESHOW
      Pets Improve Your Health
      SLIDESHOW
       

      WebMD Special Sections